GlassScriptPhysician profile
Judith A Ortman-Nabi
NPI 1699731141
$10,762.16
in general payments reported to CMS, 2019-2025
49 companies · $44.67 in 2025
The $44.67 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,640 · 2020: $1,330 · 2021: $2,135 · 2022: $2,454 · 2023: $2,154 · 2024: $1,004 · 2025: $44.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.01 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $986.62 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $889.32 | 2019-2024 | Xifaxan, Trulance |
| Therapeuticsmd, INC. | $699.26 | 2019-2022 | |
| Astellas Pharma US INC | $462.63 | 2022-2024 | Veozah, Myrbetriq |
| Agile Therapeutics, INC. | $449.37 | 2021-2024 | Twirla |
| Amgen INC. | $440.92 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $440.60 | 2019-2024 | |
| Daiichi Sankyo INC. | $406.76 | 2019-2024 | Injectafer |
| Coopersurgical, INC. | $371.94 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $322.27 | 2022-2025 | Slynd |
| Myovant Sciences INC. | $280.12 | 2021-2022 | |
| Novo Nordisk INC | $271.47 | 2020-2024 | Wegovy |
| Gilead Sciences, INC. | $252.51 | 2021-2023 | Epclusa |
| Exact Sciences Corporation | $224.12 | 2023-2024 | Cologuard Collection Kit |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $203.93 | 2019-2024 | Gardasil, Gardasil 9 |
| Inari Medical, INC. | $189.79 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Organon LLC | $174.32 | 2021-2025 | Nexplanon, Nuvaring, Jada System |
| Currax Pharmaceuticals LLC | $160.55 | 2022-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Biohaven Pharmaceutical Holding Company LTD. | $156.96 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $153.73 | 2021 | |
| Mylan Pharmaceuticals INC. | $148.98 | 2021-2022 | |
| Avion Pharmaceuticals | $138.05 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $120.26 | 2019-2020 | |
| Hologic Sales and Service, LLC | $116.46 | 2021-2024 | Aptima |
| Millicent US INC | $101.81 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.24 | 2022-2024 | |
| Evofem Biosciences, INC. | $88.66 | 2020-2022 | |
| Shield Therapeutics INC | $85.74 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $76.92 | 2023-2024 | Myfembree |
| Medela LLC | $74.91 | 2022 | |
| Lilly USA, LLC | $68.81 | 2020-2024 | Jardiance, Zepbound |
| Vertical Pharmaceuticals, LLC | $61.16 | 2019 | |
| Myriad Women'S Health, INC. | $51.91 | 2023 | Myrisk |
| Biogen, INC. | $41.89 | 2024 | |
| Covidien LP | $38.50 | 2019-2020 | |
| Lupin INC. | $35.80 | 2019-2020 | |
| Mission Pharmacal Company | $35.67 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $34.27 | 2022 | |
| Allergan, INC. | $24.67 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $23.67 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $21.03 | 2023 | Exparel |
| Roche Diagnostics Corporation | $19.99 | 2021 | |
| Si-Bone, INC. | $19.48 | 2023 | |
| Meditrina | $19.36 | 2021 | |
| Sage Therapeutics, LLC | $16.04 | 2019 | |
| Smith+Nephew, INC. | $15.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.37 | 2019 | |
| Urovant Sciences INC | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Ortman-Nabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.